QURE Healthcare
San Francisco, California, 94109, United States
NCT Number: NCT03581994
The DECART study will determine if primary care physicians, including internists and family physicians, are able to identify and address drug-drug interactions among simulated patients and whether those physicians, when given access to Aegis Drug-Drug Interaction test results, improve patient management, take steps to reduce DDI risk, and optimize unnecessary resource utilization.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
San Francisco, California, 94109, United States
The DECART study is a pre-post, two round, randomized controlled study of a nationally representative sample of 330 primary care physicians randomly assigned to a control or one of two intervention arms. Once eligibility is determined and providers are enrolled in the study, they will be asked to complete a questionnaire describing their practice and professional background. They will then care for a total of 6 CPV® simulated patients. The simulated patients will be adults aged 30-75 and present with various clinical conditions and potential drug interactions. The design and intervention consists of two rounds with an intervention among two thirds of the participants.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test results of simulated patients
Time frame: 3 months
Difference in difference between the control and the intervention group in their identification and effective treatment of DDls.
Time frame: 3 months
Difference in difference between the control and the intervention groups in the overall quality of care as measured by their combined domain and individual item CPV scores (ranging from 0% to 100%) for the 9 patient types in aggregate and by case type.
Time frame: 3 months
Rate of DDI adoption after receiving educational material on the benefits of testing in patients who are at risk.
Time frame: 3 months
Difference in health care utilization and/or costs in patients tested with DDI versus the control group in aggregate and by case type.
Qure Healthcare, LLC
Industry
Drug-Drug Interaction (DDI™) Effectiveness and Clinical Awareness Randomized Controlled Trial
Acronym: DECART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03411122
Drug-Drug Interactions
DeLand, Florida, United States
View Trial DetailsNCT07426042
Drug-Drug Interactions
View Trial Details